AbbVie Inc. $ABBV Shares Sold by SVB Wealth LLC

SVB Wealth LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 8.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 93,857 shares of the company’s stock after selling 8,492 shares during the period. AbbVie comprises 1.2% of SVB Wealth LLC’s holdings, making the stock its 18th largest position. SVB Wealth LLC’s holdings in AbbVie were worth $21,732,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ABBV. Brighton Jones LLC lifted its holdings in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Sharp Financial Services LLC boosted its holdings in AbbVie by 5.5% in the 2nd quarter. Sharp Financial Services LLC now owns 2,124 shares of the company’s stock worth $394,000 after buying an additional 110 shares during the last quarter. Ellis Investment Partners LLC increased its stake in AbbVie by 0.9% during the 2nd quarter. Ellis Investment Partners LLC now owns 7,739 shares of the company’s stock worth $1,437,000 after buying an additional 67 shares in the last quarter. Finally, Almanack Investment Partners LLC. raised its holdings in shares of AbbVie by 640.1% during the second quarter. Almanack Investment Partners LLC. now owns 10,554 shares of the company’s stock valued at $1,959,000 after acquiring an additional 9,128 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

AbbVie stock opened at $223.00 on Tuesday. The firm has a 50 day simple moving average of $223.71 and a 200-day simple moving average of $220.07. The stock has a market cap of $394.13 billion, a price-to-earnings ratio of 94.49, a price-to-earnings-growth ratio of 0.85 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research note on Tuesday, November 4th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Morgan Stanley increased their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.